+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Long-term results of patients with advanced diffuse, non-Hodgkin's lymphoma treated with cyclophosphamide, doxorubicin, vincristine, prednisone and bleomycin (CHOP-Bleo)

Long-term results of patients with advanced diffuse, non-Hodgkin's lymphoma treated with cyclophosphamide, doxorubicin, vincristine, prednisone and bleomycin (CHOP-Bleo)

Oncology 40(3): 186-191

17 patients with diffuse non-Hodgkin's lymphoma with unfavorable histologies were treated with cyclophosphamide, hydroxyldaunorubicin (doxorubicin), vincristine (Oncovin), prednisone and bleomycin (CHOP-Bleo). Of the 16 patients entering a complete remission, 8 remain in remission at 46+, 50+, 51+, 61+, 61+, 61+ and 63+ months. There were 2 treatment deaths in elderly patients, both in remission. 2 of the early relapses (less than 12 months) were later characterized as lymphoblastic lymphoma upon review of the original pathology. All 3 patients with late relapses (32, 37, and 44 months), were able to be successfully retreated. The 2 patients with lymphoblastic lymphoma developed central nervous system disease despite prophylactic intrathecal methotrexate; but central nervous system disease has not developed in the 4 other patients with initial bone marrow involvement who received prophylactic intrathecal therapy.

Please choose payment method:

(PDF emailed within 1 workday: $29.90)

Accession: 043555553

Download citation: RISBibTeXText

PMID: 6189041

Related references

Long-Term Results of Patients with Advanced Diffuse, Non-Hodgkins Lymphoma Treated with Cyclophosphamide, Doxorubicin, Vincristine, Prednisone and Bleomycin (Chop-Bleo). Oncology 40(3): 186-191, 1983

Combination chemotherapy of advanced, diffuse, non-Hodgkin's lymphoma: results with cyclo-phosphamide, adriamycin, vincristine, prednisone, and bleomycin (CHOP-Bleo). Journal of the Maine Medical Association 70(9): 348-50 352 368, 1979

Long term results of patients with advanced diffuse non hodgkins lymphoma treated with cyclo phosphamide doxorubicin vincristine prednisone and bleomycin. Oncology (Basel) 40(3): 186-191, 1983

Phase III trial of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) versus cisplatin, etoposide, bleomycin and prednisone (CisEBP) for the treatment of advanced non-Hodgkin's lymphoma of high grade malignancy. The Danish Lymphoma Study Group. Acta Oncologica 29(8): 995-999, 1990

Phase Iii Trial of Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (Chop) Versus Cisplatin, Etoposide, Bleomycin and Prednisone (CisEbp) for the Treatment of Advanced Non-Hodgkin's Lymphoma of High Grade Malignancy. Acta Oncologica 29(8): 995-999, 1990

Randomized study comparing doxorubicin, cyclophosphamide, vincristine, methotrexate with leucovorin rescue, and cytarabine (ACOMLA) with cyclophosphamide, doxorubicin, vincristine, prednisone, and bleomycin (CHOP-B) in the treatment of diffuse histiocytic lymphoma. Cancer Treatment Reports 66(6): 1279-1284, 1982

Advanced diffuse histiocytic lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) without maintenance therapy. Cancer Treatment Reports 64(4-5): 649-654, 1980

Cyclophosphamide, adriamycin, vincristine, bleomycin and prednisolone (CHOP-Bleo) combination chemotherapy for advanced non-Hodgkin's lymphoma. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 10(5): 1266-1271, 1983

The cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin, and procarbazine (COPBLAM-I) regimen for intermediate-grade non-Hodgkin's lymphoma: Long term follow-up in 51 patients. Cancer 74(11): 3029-3033, 1994

Severe pulmonary toxicity in patients with advanced-stage Hodgkin's disease treated with a modified bleomycin, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone, and gemcitabine (BEACOPP) regimen is probably related to the combination of gemcitabine and bleomycin: a report of the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology 22(12): 2424-2429, 2004

14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology 21(9): 1734-1739, 2003

CHOP-R (cyclophosphamide, doxorubicin, vincristine, prednisone, rituximab) compared to CPOP-R (cyclophosphamide, pixantrone, vincristine, prednisone, rituxamib) in first-line therapy of diffuse large B cell lymphoma (DLBCL): An interim analysis. 2007

Bleomycin, lomustine, cyclophosphamide, vincristine, procarbazine and prednisone (BLEO-CCVPP) in patients with Hodgkin's disease who relapsed after radiotherapy alone: a long-term follow-up study of the Eastern Cooperative Oncology Group (E3481). Leukemia and Lymphoma 40(3-4): 357-363, 2001

A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515. Blood 120(6): 1210-1217, 2012

Sequential therapy with alternating short courses of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) and R-FM (rituximab, fludarabine, mitoxantrone) followed by autologous stem cell transplantation results in long term remission in advanced follicular lymphoma. British Journal of Haematology 166(4): 625-628, 2014